Karyopharm announces clinical trial collaboration with bristol myers squibb to evaluate novel celmod™ agent cc- 92480 mezigdomide in combination with selinexor in patients with relapsed/refractory multiple myeloma

—  phase 1b/2 trial will investigate mezigdomide in combination with  selinexor  in patients with relapsed/refractory multiple myeloma progressing after t-cell immunotherapies – — expected to be initiated 1h 2024 – newton, mass. , oct. 30, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a clinical trial collaboration and supply agreement with bristol-myers squibb (nyse: bmy) to evaluate the company's proprietary investigational cereblon e3 ligase modulator (celmod™) agent mezigdomide in combination with karyopharm's selinexor, an approved first-in-class inhibitor of exportin 1 (xpo1), plus dexamethasone in patients with relapsed/refractory multiple myeloma.
KPTI Ratings Summary
KPTI Quant Ranking